In accordance with the EFPIA Disclosure Code and its national implementation through the Austrian association of the pharmaceutical industry (Pharmig) Bayer discloses transfers of value connected to the development and commercialization of prescription-only human pharmaceuticals to healthcare professionals and healthcare organizations.
The disclosed data include transfers of value in four main categories:
|Categories||Transfers of value:
|Donations and grants||Whether monetary or other|
|Services and consultancy||
|Research and development||Fees, travel & accommodation, and other related expenses that are covered in connection with the service|
Learn More About our Disclosure Methodology
The general rules of the EFPIA Disclosure Code and the transparency rules of the Pharmig-Code of Conduct apply to all member companies and all companies will disclose transfers of value made to healthcare professionals and healthcare organizations in a pre-defined format. However, some details of the reporting methodology are left for the individual companies to decide in order to allow the necessary flexibility to adjust to the internal processes. This methodology note allows you to understand how Bayer in
Methodology Note regarding the implementation of the EFPIA Disclosure Code, locally transposed by the “PHARMIG-Code of Conduct”.
We at Bayer are convinced that close cooperation with and continuous education of healthcare professionals are key to achieving better outcomes for the patients we strive to help. We are committed to transparency regarding how healthcare professionals (HCPs) and healthcare organizations (HCOs) are compensated by us for the time and expertise they provide. When collaborating with medical experts, we comply with applicable laws and regulations, which regulate the relationship between the pharmaceutical industry and healthcare professionals, e.g. laws of the health system and codes of conduct designed by the industry, and fully respect the independence and integrity of these professionals.
As a member of the Association of the Pharmaceutical Industry in Austria (“PHARMIG”) we feel obliged to make the nature and extent of our cooperation with healthcare professionals understandable and transparent. For this purpose the PHARMIG has amended its code of conduct accordingly (Article 9). This code is designed to ensure that even the impression of potential conflicts of interest is avoided. By making the cooperation between the industry and the medical community more transparent, the general public can gain a better understanding of the high importance and value of this cooperation.
Healthcare professionals are doctors, pharmacists and other natural persons that are members of the medical, dental, pharmacy or nursing professions or other persons who, in the course of their professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product and whose primary practice, principal professional address or place of incorporation is in Europe. This also includes employees of public bodies, sick funds or other payers, who are in charge of prescribing, purchasing or administering drugs or are deciding about reimbursement.
In order to make the nature and the extent of the interaction between the pharmaceutical industry and healthcare professionals and organizations more transparent, Bayer will document and disclose all Transfers of Value in scope of the PHARMIG-Code of Conduct, dated July 1, 2015, which it makes, directly or indirectly, to the benefit of HCPs or HCOs. The reporting period is always a full calendar year and the report will always be published until end of June of the following year.
The purpose of this methodology note is to allow any person accessing the report to understand how Bayer is documenting and disclosing the relevant information in line with the PHARMIG-Code of Conduct. It shall especially explain the details of the data collection and reporting methodology.
If in doubt about the duty to disclose a specific Transfer of Value, our company will always aim for full disclosure. Only if a Transfer of Value is clearly out of scope of the Disclosure Code, it will not be included in the published report. This methodology note is structured as follows: Based on a specific question, we will explain in detail, how Bayer handles disclosure of Transfers of Value to HCPs and HCOs according to the PHARMIG-Code of Conduct.